Type Public Industry Biotechnology CEO Hans Bishop (Sep 2013–) | Traded as NASDAQ: JUNO Website junotherapeutics.com Founded 2013 | |
Key people Hans Bishop (CEO & President)
Steve Harr, M.D. (CFO)
Hyam Levitsky, M.D. (CSO)
Mark Gilbert, M.D. (CMO) Stock price JUNO (NASDAQ) US$ 23.81 +0.06 (+0.25%)15 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters Seattle, Washington, United States Subsidiaries RedoxTherapies Inc., STAGE cell therapeutics GmbH, X-BODY, Inc., ZetaRx Biosciences, Inc., AbVitro LLC | ||
Juno therapeutics ceo bishop on immunotherapy
Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO.
Contents
Company History
In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22.
In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of Astra Zeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. In June, the company announced it would acquire X-Body for more than $44 million. In June, the company announced a 10-year partnership with Celgene valued at $1 billion. As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno’s therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014.
In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets. Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen.